MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN

Oncotarget

Volumn 6, Issue 8, 2015, Pages 5932-5946

  Wang, Li Juan ^a   He, Chen Chen ^a   Sui, Xin ^a   Cai, Meng Jiao ^a   Zhou, Cong Ya ^a   Ma, Jin Lu ^a   Wu, Lei ^a,b   Wang, Hao ^a,b   Han, Su Xia ^a   Zhu, Qing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b Shaanxi Provincial Tumor Hospital   (China)

Author keywords

Intrahepatic cholangiocarcinoma; MiR 21; PTEN; PTPN14; Tumorigenesis

Indexed keywords

MICRORNA 21; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE NON RECEPTOR TYPE 14; UNCLASSIFIED DRUG; MICRORNA; MIRN21 MICRORNA, HUMAN; PTEN PROTEIN, HUMAN; PTPN14 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; BLOOD LEVEL; CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN TARGETING; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BILE DUCT TUMOR; BIOSYNTHESIS; BLOOD; GENETIC TRANSFECTION; GENETICS; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BILE DUCT NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; FEMALE; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR; PTEN PHOSPHOHYDROLASE; TRANSFECTION;

EID: 84925605532     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3465     Document Type: Article

References (50)

1. Zhang GW, Lin JH, Qian JP and Zhou J. Identification of Risk and Prognostic Factors for Patients with Clonorchiasis-Associated Intrahepatic Cholangiocarcinoma. Annals of surgical oncology. 2014.
2. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL and Nagorney DM. Biliary tract cancers. The New England journal of medicine. 1999; 341(18):1368-1378.
3. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64(1):9-29.
4. Blechacz B and Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008; 48(1):308-321.
5. Patel T. New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma. Journal of gastroenterology. 2014; 49(2):165-172.
6. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001; 33(6):1353-1357.
7. Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E and La Vecchia C. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2013; 24(6):1667-1674.
8. de Martel C, Plummer M and Franceschi S. Cholangiocarcinoma: descriptive epidemiology and risk factors. Gastroenterologie clinique et biologique. 2010; 34(3):173-180.
9. Dhanasekaran R, Hemming AW, Zendejas I, George T, Nelson DR, Soldevila-Pico C, Firpi RJ, Morelli G, Clark V and Cabrera R. Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. Oncology reports. 2013; 29(4):1259-1267.
10. Zhou XD, Tang ZY, Fan J, Zhou J, Wu ZQ, Qin LX, Ma ZC, Sun HC, Qiu SJ, Yu Y, Ren N, Ye QH, Wang L and Ye SL. Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5, 829 patients with hepatocellular carcinoma. Journal of cancer research and clinical oncology. 2009; 135(8):1073-1080.
11. Farley DR, Weaver AL and Nagorney DM. "Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clinic proceedings. 1995; 70(5):425-429.
12. Ho KC, Wang CC, Qiu JT, Lai CH, Hong JH, Huang YT, Huang KG, Chao A, Lin G and Yen TC. Identification of prognostic factors in patients with cervical cancer and supraclavicular lymph node recurrence. Gynecologic oncology. 2011; 123(2):253-256.
13. Blechacz B, Komuta M, Roskams T and Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nature reviews Gastroenterology & hepatology. 2011; 8(9):512-522.
14. Cummins JM and Velculescu VE. Implications of micro-RNA profiling for cancer diagnosis. Oncogene. 2006; 25(46):6220-6227.
15. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215-233.
16. Calin GA and Croce CM. MicroRNA signatures in human cancers. Nature reviews Cancer. 2006; 6(11):857-866.
17. Kumar MS, Lu J, Mercer KL, Golub TR and Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nature genetics. 2007; 39(5):673-677.
18. Croce CM and Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005; 122(1):6-7.
19. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-297.
20. Gregory RI and Shiekhattar R. MicroRNA biogenesis and cancer. Cancer research. 2005; 65(9):3509-3512.
21. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(30):10513-10518.
22. Silakit R, Loilome W, Yongvanit P, Chusorn P, Techasen A, Boonmars T, Khuntikeo N, Chamadol N, Pairojkul C and Namwat N. Circulating miR-192 in liver fluke-associated cholangiocarcinoma patients: a prospective prognostic indicator. Journal of hepato-biliary-pancreatic sciences. 2014.
23. Wang LG and Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer epidemiology. 2012; 36(1):e61-67.
24. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS and Sung JJ. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009; 58(10):1375-1381.
25. Li B, Han Q, Zhu Y, Yu Y, Wang J and Jiang X. Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. The FEBS journal. 2012; 279(13):2393-2398.
26. Zhang J, Han C and Wu T. MicroRNA-26a promotes cholangiocarcinoma growth by activating beta-catenin. Gastroenterology. 2012; 143(1):246-256 e248.
27. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007; 133(2):647-658.
28. Yao Q, Xu H, Zhang QQ, Zhou H and Qu LH. MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. Biochemical and biophysical research communications. 2009; 388(3):539-542.
29. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD and Patel T. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006; 130(7):2113-2129.
30. Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, Yang J, Paun B, Jin Z, Agarwal R, Hamilton JP, Abraham J, Georgiades C, Alvarez H, Vivekanandan P, Yu W, et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology. 2009; 49(5):1595-1601.
31. He Q, Cai L, Shuai L, Li D, Wang C, Liu Y, Li X, Li Z and Wang S. Ars2 is overexpressed in human cholangiocarcinomas and its depletion increases PTEN and PDCD4 by decreasing microRNA-21. Molecular carcinogenesis. 2013; 52(4):286-296.
32. Namwat N, Chusorn P, Loilome W, Techasen A, Puetkasichonpasutha J, Pairojkul C, Khuntikeo N and Yongvanit P. Expression profiles of oncomir miR-21 and tumor suppressor let-7a in the progression of opisthorchiasis-associated cholangiocarcinoma. Asian Pacific journal of cancer prevention: APJCP. 2012; 13 Suppl:65-69.
33. Wang Y, Gao X, Wei F, Zhang X, Yu J, Zhao H, Sun Q, Yan F, Yan C, Li H and Ren X. Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis. Gene. 2014; 533(1):389-397.
34. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR and Goel A. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. Journal of the National Cancer Institute. 2013; 105(12):849-859.
35. Wilson KE, Li YW, Yang N, Shen H, Orillion AR and Zhang J. PTPN14 Forms a Complex with Kibra and LATS1 Proteins and Negatively Regulates the YAP Oncogenic Function. The Journal of biological chemistry. 2014; 289(34):23693-23700.
36. Liu X, Yang N, Figel SA, Wilson KE, Morrison CD, Gelman IH and Zhang J. PTPN14 interacts with and negatively regulates the oncogenic function of YAP. Oncogene. 2013; 32(10):1266-1273.
37. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM and Harris CC. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA: the journal of the American Medical Association. 2008; 299(4):425-436.
38. Chang KH, Miller N, Kheirelseid EA, Ingoldsby H, Hennessy E, Curran CE, Curran S, Smith MJ, Regan M, McAnena OJ and Kerin MJ. MicroRNA-21 and PDCD4 expression in colorectal cancer. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2011; 37(7):597-603.
39. Chan SH, Wu CW, Li AF, Chi CW and Lin WC. miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer research. 2008; 28(2A):907-911.
40. Liu C, Yu J, Yu S, Lavker RM, Cai L, Liu W, Yang K, He X and Chen S. MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. Journal of hepatology. 2010; 53(1):98-107.
41. Huang Q, Liu L, Liu CH, You H, Shao F, Xie F, Lin XS, Hu SY and Zhang CH. MicroRNA-21 regulates the invasion and metastasis in cholangiocarcinoma and may be a potential biomarker for cancer prognosis. Asian Pacific journal of cancer prevention: APJCP. 2013; 14(2):829-834.
42. Cheng AM, Byrom MW, Shelton J and Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic acids research. 2005; 33(4):1290-1297.
43. Chan JA, Krichevsky AM and Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer research. 2005; 65(14):6029-6033.
44. Michaloglou C, Lehmann W, Martin T, Delaunay C, Hueber A, Barys L, Niu H, Billy E, Wartmann M, Ito M, Wilson CJ, Digan ME, Bauer A, Voshol H, Christofori G, Sellers WR, et al. The tyrosine phosphatase PTPN14 is a negative regulator of YAP activity. PloS one. 2013; 8(4):e61916.
45. Tumaneng K, Schlegelmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan N, Fitamant J, Bardeesy N, Camargo FD and Guan KL. YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nature cell biology. 2012; 14(12):1322-1329.
46. Tumaneng K, Russell RC and Guan KL. Organ size control by Hippo and TOR pathways. Current biology: CB. 2012; 22(9):R368-379.
47. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R and Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science. 1998; 280(5369):1614-1617.
48. Ramos A and Camargo FD. The Hippo signaling pathway and stem cell biology. Trends in cell biology. 2012; 22(7):339-346.
49. Xiao J, Luo X, Lin H, Zhang Y, Lu Y, Wang N, Zhang Y, Yang B and Wang Z. MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. The Journal of biological chemistry. 2007; 282(17):12363-12367.
50. Wang L, Shi S, Guo Z, Zhang X, Han S, Yang A, Wen W and Zhu Q. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PloS one. 2013; 8(6):e65539.